Last Updated on July 27, 2022 by GlobeNewsWire
WATERTOWN, Mass., July 27, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report second quarter 2022 financial results on August 9, 2022 and will host a conference call at 8:30 a.m. ET that day.
To access the conference call via phone, please dial 877-317-6789 (U.S.) or +1-412-317-6789 (International) and ask to join the Kymera Therapeutics call. A live webcast of the event will be available under “Events and Presentations” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available for one month following the event.
About Kymera TherapeuticsKymera Therapeutics (Nasdaq: KYMR) is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional therapeutics. Kymera’s Pegasus platform is a powerful drug discovery engine, advancing novel small molecule therapies that harness the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. With a focus on undrugged nodes in validated pathways, Kymera is advancing a pipeline of novel therapeutics designed to address the most intractable pathways and provide new treatments for patients. Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat patients with a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. For more information, visit http://www.kymeratx.com.
Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a “Fierce 15” biotechnology company by Fierce Biotech and has been recognized by the Boston Business Journal as one of Boston’s “Best Places to Work.” For more information about our people, science, and pipeline, please visit http://www.kymeratx.com or follow us on Twitter or LinkedIn.
Investor Contact:Bruce Jacobs Chief Financial Officer investors@kymeratx.com857-285-5300
Chris BrinzeyManaging Director, Westwickechris.brinzey@westwicke.com339-970-2843
Media Contact:Todd Cooper Senior Vice President, Corporate Affairsmedia@kymeratx.com 857-285-5300
Leave a Reply